Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial
Background N-methyl-D-aspartate receptor (NMDAR)-mediated neurotransmission is vital
for learning and memory. Hypofunction of NMDAR has been reported to play a role in the …
for learning and memory. Hypofunction of NMDAR has been reported to play a role in the …
Precision medicine of sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD)
Objective Behavioral and psychological symptoms of dementia (BPSD) are associated with
poorer prognosis of dementia. A 24-week study demonstrated that sodium benzoate, a D …
poorer prognosis of dementia. A 24-week study demonstrated that sodium benzoate, a D …
Brain activity of benzoate, a D-amino acid oxidase inhibitor, in patients with mild cognitive impairment in a randomized, double-blind, placebo controlled clinical trial
Background Current anti-dementia drugs cannot benefit mild cognitive impairment (MCI).
Sodium benzoate (a D-amino acid oxidase [DAO] inhibitor) has been found to improve the …
Sodium benzoate (a D-amino acid oxidase [DAO] inhibitor) has been found to improve the …
Effect of sodium benzoate on cognitive function among patients with behavioral and psychological symptoms of dementia: secondary analysis of a randomized clinical …
Importance Female gender is a major risk factor for dementia; however, gender has not yet
been adequately addressed by clinical trials. A recent study demonstrated that sodium …
been adequately addressed by clinical trials. A recent study demonstrated that sodium …
Endogenous antioxidants predicted outcome and increased after treatment: A benzoate dose‐finding, randomized, double‐blind, placebo‐controlled trial for …
Aim Previous pilot studies suggest that sodium benzoate may be a potential cognitive
enhancer for patients with Alzheimer's disease (AD), schizophrenia, or late‐life depression …
enhancer for patients with Alzheimer's disease (AD), schizophrenia, or late‐life depression …
NMDA neurotransmission dysfunction in mild cognitive impairment and Alzheimer's disease
The prevalence of Alzheimer's disease (AD) in the elderly is growing rapidly worldwide, and
the deteriorating clinical course of AD places a heavy burden on both the patients and their …
the deteriorating clinical course of AD places a heavy burden on both the patients and their …
Why do many NMDA antagonists fail, while others are safe and effective at blocking excitotoxicity associated with dementia and acute injury?
BC Albensi, C Igoechi, D Janigro… - American Journal of …, 2004 - journals.sagepub.com
Similar to drug development programs for stroke and traumatic brain injury, programs
developed for Alzheimer's disease (AD) have not been very effective in treating dementia …
developed for Alzheimer's disease (AD) have not been very effective in treating dementia …
[HTML][HTML] The role of N-methyl-D-aspartate receptor neurotransmission and precision medicine in behavioral and psychological symptoms of dementia
While the world's population is aging, the prevalence of dementia and the associated
behavioral and psychological symptoms of dementia (BPSD) rises rapidly. BPSD are …
behavioral and psychological symptoms of dementia (BPSD) rises rapidly. BPSD are …
Role of glutamate and NMDA receptors in Alzheimer's disease
Excitatory glutamatergic neurotransmission via N-methyl-d-aspartate receptor (NMDAR) is
critical for synaptic plasticity and survival of neurons. However, excessive NMDAR activity …
critical for synaptic plasticity and survival of neurons. However, excessive NMDAR activity …
Overexpression of NMDAR2B in an inflammatory model of Alzheimer's disease: modulation by NOS inhibitors
Background Alzheimer's disease (AD) is a common form of age-related dementia,
characterized by deposition of amyloid Aβ plaques, neuroinflammation and …
characterized by deposition of amyloid Aβ plaques, neuroinflammation and …